Pharmafile Logo
Pharmafocus logo
Advanced Search

Gastrointestinal tract

Showing 15 posts of 29 posts found.

Enzybel Pharma 2 and Deebio partner to address pancrelipase shortages

August 15, 2025
Manufacturing and Production, Mergers and Acquisitions Deebio, Enzybel Pharma 2, Gastrointestinal tract, Natix, pancrelipase

Enzybel Pharma 2, part of European distributor Natix, has formed an alliance with Chinese enzyme manufacturer Deebio to help alleviate …

News

Polpharma Biologics and Fresenius Kabi partner to develop treatment for ulcerative colitis and Crohn’s disease

August 5, 2025
Mergers and Acquisitions Corporate, Crohn’s disease, Fresenius Kabi, Gastrointestinal tract, Polpharma Biologics, ulcerative colitis

Polpharma Biologics has signed a global licensing agreement with Fresenius Kabi for the commercialisation of PB016, a proposed biosimilar to …

News
bowel_cancer_screening

NICE recommends NHS use of mirikizumab for Crohn’s disease

July 11, 2025
Medical Communications, Research and Development Crohn’s disease, Gastrointestinal tract, Medicines and Healthcare products Regulatory Agency, NHS, National Institute for Health and Care Excellence (NICE), bowel disease, clinical trial

Eli Lilly (Lilly) has announced that the National Institute for Health and Care Excellence (NICE) has recommended mirikizumab (omvoh) for …

News
baby-2416718_1280

Study into treatment for rare condition in premature infants launches globally

June 9, 2025
Research and Development Chiesi Farmaceutici, Elgan Pharma, Gastrointestinal tract, Paediatrics, clinical trial, intestinal malabsorption, premature infant health

Elgan Pharma, specialising in neonatology, and Italy-based biopharma, Chiesi Farmaceutici, have announced the dosing of the first participating infants in …

News
clinical_trials_2

NICE recommends mirikizumab (Omvoh â–¼) for previously treated moderately to severely active Crohn’s disease 1

May 30, 2025
Research and Development Crohn’s disease, Eli Lilly and Company, Gastrointestinal tract, Medicines and Healthcare products Regulatory Agency (MHRA)(, NHS England and Wales, National Institute for Health and Care Excellence (NICE), Omvoh, inflammatory bowel disease (IBD), mirikizumab

In the Phase 3 VIVID-1 trial, patients treated with mirikizumab experienced significant improvement in clinical remission and endoscopic response at …

News
Press release
bowel_cancer_screening

European Commission approves Johnson & Johnson’s Crohn’s disease therapy

May 12, 2025
Market Access, Research and Development, Sales and Marketing Crohn’s disease, European Commission, Gastrointestinal tract, Johnson & Johnson, guselkumab, marketing authorisation

The European Commission (EC) has granted Marketing Authorisation (MA) to Johnson & Johnson’s Tremfya (guselkumab) for the treatment of moderately …

News

Biomarkers used in trial to prevent systematic onset of Crohns Disease before it begins in Europe-first project 

January 22, 2025
Research and Development Crohns Disease, Crohsn, Gastrointestinal tract, Takeda, biomarkers, ibd, project

Takeda, a global biopharmaceutical company, is due to launch a project, INTERCEPT, which will use biomarkers to prevent symptomatic onset …

News

Ferring demonstrates effectiveness of a treat-to-target approach in mild-to-moderate ulcerative colitis in first major study

October 3, 2024
Research and Development Ferring Pharmaceuticals, Gastrointestinal tract, ulcerative colitis

1 October 2024 – Saint-Prex, Switzerland – Ferring Pharmaceuticals today announces results from the OPTIMISE study showing the first real-world …

News
Press release
bowel_cancer_screening

The National Institute for Health and Care Excellence announce technology appraisal guidance recommending risankizumab for adult patients with moderate to severe ulcerative colitis

August 29, 2024
Research and Development AbbVie, Crohns, Gastrointestinal tract, Immunology, NICE, approval, ulcerative colitis

The National Institute for Health and Care Excellence (NICE) have recommended adult patients in England or Wales with moderately or …

News

New gastric & gastro-oesophageal junction cancer treatment VYLOYâ„¢ â–¼ (zolbetuximab): the first claudin 18.2 biomarker targeted therapy licensed in Great Britain

August 16, 2024
GEJ cancers, Gastrointestinal tract, MHRA, Oncology, gastric cancer

Claudin18.2 is an innovative drug-target which is not currently used for any other authorised treatment. There is a large unmet …

News
Press release

FDA release statement exercising caution around dosing errors associated with compounded injectable semaglutide products

July 31, 2024
Media Relations, Medical Communications, Pharmacovigilance, US Healthcare & Trade Press FDA, Gastrointestinal tract, compunded injectable, dosage, hospitalisation, pharmaceutical, warning

This week, the US Food and Drug Administration (FDA) and have issued warnings regarding dosing errors associated with compounded injectable …

News

FDA approves AbbVie’s Skyrizi for UC treatment

June 20, 2024
Medical Communications AbbVie, FDA, Gastrointestinal tract, UC, ibd

AbbVie has announced that the US Food and Drug Administration (FDA) has approved Skyrizi (risankizumab-rzaa) for the treatment of adult …

News

AbbVie and FutureGen announce license agreement for IBD therapy

June 14, 2024
Research and Development FutureGen, Gastrointestinal tract, ibd, inflammatory bowel disease

AbbVie and FutureGen Biopharmaceutical have announced a license agreement for the development of FG-M701, a next-generation TL1A antibody for the …

News

AbbVie gains positive CHMP opinion for Skyrizi for treatment of UC

May 31, 2024
Medical Communications AbbVie, EMA, Gastrointestinal tract, Skyrizi, ulcerative colitis

AbbVie has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted a …

News

J&J’s Tremfya meets primary and secondary endpoints in UC maintenance study

May 21, 2024
Medical Communications Gastrointestinal tract, J&J, Johnson & Johnson, clinical trial, ulcerative colitis

Johnson & Johnson (J&J) has announced the first data from its phase 3 QUASAR maintenance study which assessed Tremfya (guselkumab) …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025